Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors

This study has been terminated.
Information provided by (Responsible Party):
Bristol-Myers Squibb Identifier:
First received: May 22, 2009
Last updated: June 17, 2013
Last verified: June 2013
The study is expected to identify a safe dose of BMS-754807 to be given in combination with a standard dose of cetuximab and the recommended dose or dose range for Phase II studies. The study is also intended to collect first data on the effects of the combination of BMS-754807 with cetuximab on tumors of patients with colorectal cancer or squamous cell cancer of the head and neck for whom cetuximab-containing therapies have not been effective

Condition Intervention Phase
Colorectal Cancer
Head and Neck Cancer
Neoplasm Metastasis
Drug: BMS-754807
Drug: cetuximab (Erbitux®)
Phase 1
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I/II Trial of BMS-754807 in Combination With Cetuximab (Erbitux®) in Subjects With Advanced or Metastatic Solid Tumors

Resource links provided by NLM:

Further study details as provided by Bristol-Myers Squibb:

Primary Outcome Measures:
  • Maximum tolerated dose of BMS-754807 administered orally (daily schedule) in combination with cetuximab administered standard doses IV (weekly basis) will be determined by observation of dose limiting toxicities during the first 33 days of administration [ Time Frame: During and at the end of the first 33 days after the first dose of BMS-754807 is given ]

Secondary Outcome Measures:
  • To assess anti-tumor activity as measured by objective responses [ Time Frame: every 8 weeks ]
  • To evaluate the safety and tolerability of the BMS-754807/cetuximab combination regimen [ Time Frame: Ongoing ]
  • To assess the effects of the BMS-754807/cetuximab combination regimen on glucose homeostasis [ Time Frame: Ongoing ]
  • Dose Expansion only: To identify biomarkers that are predictive of a response to BMS-754807/cetuximab combination therapy in advanced or metastatic CRC and SCCHN subjects with cetuximab resistance [ Time Frame: tumor biopsies before treatment and on day 33 +/- 3 of treatment ]

Enrollment: 54
Study Start Date: October 2009
Study Completion Date: December 2012
Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: BMS-754807 + cetuximab
Drug: BMS-754807
Tablets, Oral, doses vary during dose escalation, once daily, varies - treatment is continued to disease progression or MD/subject/sponsor decision
Drug: cetuximab (Erbitux®)
IV infusion, IV, 400 mg/m² loading dose, then 250 mg/m², weekly, varies - treatment is continued to disease progression or MD/subject/sponsor decision
Other Name: Eributux®


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

For additional information, please contact the BMS oncology clinical trial information service at 855-216-0126 or email Please visit for more information on clinical trial participation.

Inclusion Criteria:

  • ECOG status 0 - 1
  • Dose escalation: Subjects with locally advanced or metastatic solid tumors who are eligible to receive cetuximab treatment and have archived tumor biopsy material available. Colorectal cancer subjects must be confirmed KRAS wild type
  • Dose expansion: CRC (KRAS-WT) and head & neck cancer subjects only

    1. must be able to provide 2 fresh tumor biopsy samples
    2. must have failed one prior cetuximab-containing treatment

Exclusion Criteria:

  • Symptomatic brain metastasis
  • Prior treatments with anti-EGFR (except cetuximab) or anti-IGF-1R agents, experimental or licensed
  • Any condition requiring chronic use of steroids
  • Any disorder with dysregulation of glucose homeostasis (history of Type 1 or 2 Diabetes Mellitus or prediabetic symptoms)
  • History of glucose intolerance
  • History of cetuximab infusion reactions
  • Women of child-bearing potential unwilling or unable to use acceptable contraception methods
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00908024

United States, Nebraska
Nebraska Methodist Hospital
Omaha, Nebraska, United States, 68114
United States, North Carolina
Duke University Medical Center
Durham, North Carolina, United States, 27710
United States, Wisconsin
University Of Wisconsin
Madison, Wisconsin, United States, 53705
Canada, British Columbia
Local Institution
Vancouver, British Columbia, Canada, V5Z 4E6
Canada, Ontario
Local Institution
Toronto, Ontario, Canada, M5G 2M9
Sponsors and Collaborators
Bristol-Myers Squibb
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
  More Information

Additional Information:
Responsible Party: Bristol-Myers Squibb Identifier: NCT00908024     History of Changes
Other Study ID Numbers: CA191-006
EUDRACT: 2009-013766-78
Study First Received: May 22, 2009
Last Updated: June 17, 2013

Additional relevant MeSH terms:
Colorectal Neoplasms
Head and Neck Neoplasms
Neoplasm Metastasis
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Neoplastic Processes
Pathologic Processes
Antineoplastic Agents processed this record on April 28, 2017